Search

Accumulation of microtubule associated protein tau in the substantia nigra is associated with several tauopathies including progressive supranuclear palsy (PSP). A number of studies have used mutant tau transgenic mouse model to mimic the neuropathology of tauopathies and disease phenotypes. However, tau expression in these transgenic mouse models is not specific to brain subregions, and may not recapitulate subcortical disease phenotypes of PSP. It is necessary to develop a new disease modeling system for cell and region-specific expression of pathogenic tau for modeling PSP in mouse brain. In this study, we developed a novel strategy to express P301L mutant tau to the dopaminergic neurons of substantia nigra by coupling tyrosine hydroxylase promoter Cre-driver mice with a Cre-inducible adeno-associated virus (iAAV). The results showed that P301L mutant tau was successfully transduced in the dopaminergic neurons of the substantia nigra at the presence of Cre recombinase and iAAV. Furthermore, the iAAV-tau-injected mice displayed severe motor deficits including impaired movement ability, motor balance, and motor coordination compared to the control groups over a short time-course. Immunochemical analysis revealed that tau gene transfer significantly resulted in loss of tyrosine hydroxylase-positive dopaminergic neurons and elevated phosphorylated tau in the substantia nigra. Our development of dopaminergic neuron-specific neurodegenerative mouse model with tauopathy will be helpful for studying the underlying mechanism of pathological protein propagation as well as development of new therapies., (Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.)

When bearing certain frontotemporal dementia with parkinsonism (FTDP) mutations, overexpression of human tau resulted in a decrease of the dentate gyrus ventral blade, apparently due to a reduction in the proliferation of neuronal precursors and an increase in neuronal cell death. This degenerative process was accompanied by a dramatic increase in behavioral despair, as evident in the Porsolt swim test. Interestingly, we observed an increase in GABAergic innervation in the molecular layer of the dorsal dentate gyrus but not in the ventral domain. We suggest that this increase in GABAergic innervation reflects a compensatory neuroprotective response to the overexpression of toxic tau, which may prevent or delay degeneration in the dorsal blade of the dental gyrus. Finally, we suggest that this transgenic mouse, which overexpresses human FTPD tau, may serve as a useful model to study specific functions of the ventral dentate gyrus., (Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.)

The present study quantified the cleaved form of the microtubule-associated protein tau (cleaved MAP-tau, C-tau), a previously demonstrated marker of CNS toxicity, following the administration of monoamine-depleting regimens of the psychostimulant drugs amphetamine (AMPH), methamphetamine (METH), +/-3,4-methylenedioxymethamphetamine (MDMA), or para-methoxyamphetamine (PMA) in an attempt to further characterize psychostimulant-induced toxicity. A dopamine (DA)-depleting regimen of AMPH produced an increase in C-tau immunoreactivity in the striatum, while a DA- and serotonin (5-HT)-depleting regimen of METH produced an increase in the number of C-tau immunoreactive cells in the striatum and CA2/CA3 and dentate gyrus regions of the hippocampus. MDMA and PMA, two psychostimulant drugs that produce selective 5-HT depletion in the striatum, had no effect on C-tau immunoreactivity in the striatum or hippocampus. Furthermore, 5,7-dihydroxytryptamine (5,7-DHT), an established 5-HT selective neurotoxin, did not produce an increase in C-tau immunoreactivity. Dual fluorescent immunocytochemistry with antibodies to glial fibrillary acidic protein (GFAP) and C-tau indicated that C-tau immunoreactivity was present in astrocytes, not neurons, suggesting that increased C-tau may be an alternative indicator of reactive gliosis. The present results are consistent with previous findings that the DA-depleting psychostimulants AMPH and METH produce reactive gliosis whereas the 5-HT-depleting drugs MDMA and PMA, as well as the known 5-HT selective neurotoxin 5,7-DHT, do not produce an appreciable glial response.

We have studied the expression of genes for neuronal microtubule-associated proteins in organotypic hippocampal slice cultures using immunoblotting and polymerase chain reaction combined with reverse transcription on a single-slice basis. We found that for microtubule-associated protein 2 and tau the same developmental transition from embryonic to adult splice variants occurs in the cultures as has been described previously in intact brain. This finding indicates that the maturation profile of these proteins is not determined by extrinsic inputs but by a cell-autonomous programme or local factors within the hippocampus. Our study corroborates previous data for the maturation of hippocampal slice cultures and is also the first biochemical analysis on the level of the neuronal cytoskeleton of this widely used model system for the hippocampus.

The microtubule-associated protein tau is more highly phosphorylated at certain residues in developing brain and in Alzheimer's disease paired helical filaments than in adult brain. We examined the regulation of tau phosphorylation at some of these sites in rat brain using the phosphorylation state-dependent anti-tau antibodies AT8, Tau1, and PHF1. The AT8 and PHF1 antibodies bind to phosphorylated tau, while Tau1 binds to unphosphorylated tau. Levels of tau reactive for AT8 were high only during the first postnatal week, with levels in adult declining to approximately 5% of the levels in neonates. In neonatal forebrain slices, tau became rapidly dephosphorylated at the AT8 and Tau1 sites during incubation at 34 degrees C, but was incompletely dephosphorylated at the PHF1 site. Dephosphorylation at AT8 sites, but not at Tau1 or PHF1 sites, was completely inhibited by 1 microM okadaic acid. Hence the regulation of tau phosphorylation by okadaic acid-sensitive phosphatase(s) was site-specific. Addition of 1 microM okadaic acid after dephosphorylation at the AT8 locus yielded a partial recovery of AT8 immunoreactivity, and incubation with basic fibroblast growth factor increased phosphorylation at the AT8 site in a dose-dependent manner. These results indicate that endogenously active and basic fibroblast growth factor stimulated tau kinases directed toward an Alzheimer's disease-related site were present in the slices. In adult brain slices, the small pool of AT8-reactive tau was remarkably insensitive to dephosphorylation during incubation, and okadaic acid treatment induced only small increases in AT8 immunoreactivity. These results suggest that tau phosphorylation in adult brain is less dynamic than in neonatal brain. These findings indicate that neonatal tau is not only phosphorylated more highly than adult tau, but also more dynamically regulated by protein phosphatases and protein kinases than adult tau. The inability of okadaic acid to induce large increases in tau phosphorylation in adult rat brain slices suggests that a loss of protein phosphatase activity alone would not be sufficient to produce the hyperphosphorylation observed in Alzheimer's disease paired helical filaments. Stimulation of kinase activity by basic fibroblast growth factor is likely to modulate tau function during development, and may contribute to the genesis of hyperphosphorylated tau in Alzheimer's disease.

Microtubule-associated proteins contribute to the balance between stability and plasticity of the neuronal cytoskeleton by modulating assembly and disassembly of microtubules. The tau microtubule-associated proteins exist in several isoforms which are developmentally regulated and differentially distributed. Our objective was to characterize the distribution of tau isoforms in developing and mature dorsal root ganglia neurons and during axonal regeneration following sciatic nerve axotomy. Immunocytochemical analysis was carried out using antibodies that recognize all tau isoforms and a novel antibody that specifically recognizes the high molecular weight isoform. The expression of tau is highly regulated during development. At E14, all dorsal root ganglion neurons express only the low molecular weight tau isoforms. These isoforms are still present in all dorsal root ganglion neurons in neonates, whereas high molecular weight tau isoforms are expressed in a subset of dorsal root ganglion neurons. The switch from low to exclusively high molecular weight tau expression begins at E18 and is completed during the first postnatal week. In the adult, high molecular weight tau is restricted to small- and medium-sized dorsal root ganglion neurons; its distribution largely coincides with the population of substance P and calcitonin gene related peptide peptidergic neurons. This differential distribution was observed in the cell body, dorsal roots and sciatic nerve axons. In contrast to the protein, however, the distribution of high molecular weight tau messenger RNA is not restricted; all dorsal root ganglion neurons express similar tau messenger RNA levels. The discrepancy between the distribution of protein and messenger RNA suggests control at the post-transcriptional or translational levels. Sciatic nerve axotomy which is followed by axonal regeneration did not alter the differential distribution of high molecular weight tau immunostaining. We conclude that the distribution and expression of tau isoforms during axonal regeneration in adult does not recapitulate the developmental pattern.

Microtubule associated proteins play a central role in the control of axon growth. We have used immunohistochemical techniques to establish which microtubule-associated proteins are present in the rat hindlimb spinal cord, dorsal root ganglia and peripheral nerves during axonal growth during embryogenesis, in adulthood, and during regeneration of crushed sciatic nerves. During embryogenesis microtubule-associated protein-1b and tau are present in all neurons and axons, microtubule-associated protein-2 is present in neurons but not in axons, and there is no microtubule-associated protein-1a. In adults, microtubule-associated protein-1a and microtubule-associated protein-1b are present in all sciatic nerve axons and in motor and dorsal root ganglion neurons. Tau, in its adult form, is present in many fine probably sensory axons, but not in most larger axons, and in motor and sensory neurons. Microtubule-associated protein-2 is present only in neurons. During regeneration the pattern of microtubule-associated protein expression retains the adult pattern. All regenerating axons contain microtubule-associated protein-1a and microtubule-associated protein-1b, none contain microtubule-associated protein-2, and a subset of fine axons contain tau. There is no detectable change in microtubule-associated protein expression by motoneurons. While axons are clearly able to regenerate without either microtubule-associated protein-2 or tau, tau containing axons appear to regenerate faster than those which lack it. It is possible that the failure of neurons to recapitulate the embryonic pattern of microtubule-associated protein expression during regeneration could be a reason why regenerative axon growth is slower and less vigorous than axon growth in embryos.